Delving into the Latest Updates on Nerandomilast with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

A thienopyrimidine derivative that preferentially inhibits Phosphodiesterase 4B, BI 1015550, BI-1015550

+ [2]

Target

PDE4B

Action

inhibitors

Mechanism

PDE4B inhibitors(Phosphodiesterase 4B inhibitors)

Therapeutic Areas

Respiratory DiseasesOther DiseasesImmune System Diseases+ [1]

Active Indication

Idiopathic Pulmonary FibrosisProgressive pulmonary fibrosisIdiopathic Interstitial Pneumonias+ [3]

Inactive Indication-

Originator Organization

Boehringer Ingelheim Pharmaceuticals, Inc.

Active Organization

Boehringer Ingelheim International GmbHBoehringer Ingelheim Pharma GmbH & Co., KG

Boehringer Ingelheim GmbH

+ [2]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (07 Oct 2025),

Idiopathic Pulmonary Fibrosis

RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC20H25ClN6O2S

InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N

CAS Registry1423719-30-5

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.
Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.
Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.
Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Start Date23 Jan 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06241560

/ Not yet recruitingPhase 2

An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.
Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.
Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

Start Date20 Oct 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT06806592

/ RecruitingPhase 3

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease.
Participants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date13 Sep 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Nerandomilast

Login to view more data

100 Translational Medicine associated with Nerandomilast

Login to view more data

100 Patents (Medical) associated with Nerandomilast

Login to view more data

27

Literatures (Medical) associated with Nerandomilast

01 Nov 2025·AUTOIMMUNITY REVIEWS

Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases

Review

Author: Inoue, Yoshikazu ; Kondoh, Yasuhiro ; Fujii, Takao ; Atsumi, Tatsuya

Autoimmune connective tissue disease associated with interstitial lung disease (CTD-ILD) includes rheumatoid arthritis-associated ILD, systemic sclerosis-associated-ILD, and several other ILDs. Many patients with CTD-ILD-as well as individuals with other ILDs-develop a progressive pulmonary fibrosis (PPF) similar to idiopathic pulmonary fibrosis (IPF). PPF is characterized by worsening respiratory symptoms, declining lung function despite current pharmacotherapies, and ultimately early death. Current pharmacotherapies for CTD-ILD and PPF include glucocorticoids, immunosuppressants, and anti-fibrotic agents. Due to the scarcity of randomized clinical trials for CTD-ILD, many pharmacotherapies are generally administered off-label (although several are approved in Japan), with notable exceptions including nintedanib, an anti-fibrotic agent approved for SSc-ILD and chronic progressive fibrosing ILD in several countries. As the available agents only slow the decline of pulmonary function and are associated with treatment-limiting side effects, there is a need for more efficacious and tolerable pharmacotherapies for CTD-ILD and PPF. Promising compounds in clinical trials include nerandomilast (a preferential phosphodiesterase 4B inhibitor), admilparant (a lysophosphatidic acid receptor 1 antagonist), and inhaled treprostinil (a prostacyclin analogue). Nerandomilast may have both anti-fibrotic and immunomodulatory properties; in preclinical models of PPF, it reduced neutrophils and macrophages and down-regulated pro-fibrotic signaling pathways. Hopefully, therefore, this pipeline will produce new medications to ease the collectively large burden of CTD-ILD and PPF.

02 Oct 2025·NEW ENGLAND JOURNAL OF MEDICINE

Nerandomilast in Patients with Pulmonary Fibrosis

Letter

Author: Maher, Toby M ; Richeldi, Luca ; Zoz, Donald F

01 Aug 2025·Nature Reviews Rheumatology

Nerandomilast slows progression of pulmonary fibrosis

Article

Author: Papatriantafyllou, Maria

61

News (Medical) associated with Nerandomilast

14 Oct 2025

·www.prnewswire.com

Orsini Selected as Specialty Pharmacy Partner for Boehringer Ingelheim's JASCAYD® (nerandomilast)

JASCAYD is an FDA-approved oral therapy for the treatment of idiopathic pulmonary fibrosis (IPF) ELK GROVE VILLAGE, Ill., Oct. 14, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been chosen by Boehringer Ingelheim as a specialty pharmacy partner for JASCAYD® (nerandomilast), a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. Read the full Prescribing Information here. IPF is a progressive lung disease characterized by the gradual thickening and scarring of lung tissue. This scarring hinders the lungs' ability to efficiently transfer oxygen into the bloodstream, resulting in debilitating symptoms such as shortness of breath, persistent dry coughing, fatigue, unexplained weight loss and muscle and joint aches. JASCAYD, the fourth IPF therapy to join Orsini's Pulmonology Center of Excellence, has been shown to slow lung function decline in those living with IPF. "With over a decade of experience and more than 6,000 patients served, Orsini has established itself as a trusted leader in the IPF space," Brandon Tom, Orsini's CEO, said. "We're proud to continue our partnership with Boehringer Ingelheim in expanding our portfolio and bringing another vital therapy to the patients and families we serve." About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini's high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™. Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, visit . SOURCE Orsini WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

11 Oct 2025

·www.globenewswire.com

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1 Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF).2,3 Nerandomilast is a new treatment option for adult patients with IPF with a well-tolerated safety profile.2,3 Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.2 JASCAYD is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.2,3 “This milestone represents a new era in the treatment of IPF, a rare and debilitating chronic condition that worsens lung function. Nerandomilast has proven to slow lung function decline in IPF,” said Toby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles. “Nerandomilast is a welcome new treatment option with a well-tolerated safety profile for physicians to consider for appropriate patients.” The FDA approval is based on data from two clinical trials: FIBRONEER™-IPF (NCT05321069) and Trial 2 (NCT04419506). The primary endpoint in FIBRONEER™-IPF was the absolute change from baseline in Forced Vital Capacity (FVC), a measure of lung function,4 in mL at week 52.2,3 Nerandomilast demonstrated a significantly smaller FVC decline compared to placebo.2,3 Specifically, the adjusted mean decline in patients receiving 18 mg or 9 mg nerandomilast was -106 mL and -122 mL, respectively, versus -170 mL in the placebo group.2 Additionally, a treatment effect was shown as early as week two with nerandomilast 18 mg compared to placebo, with changes from baseline in FVC continuing to diverge over time to week 52.2,3 “The FDA approval of nerandomilast is a pivotal moment for people living with IPF as this marks the first time in over 10 years that the treatment landscape is evolving,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “This new step forward, driven by the compelling results of the FIBRONEER™-IPF trial, underscores our unwavering commitment to change the way we treat IPF by delivering innovative therapies like nerandomilast.” The most common (≥5%) adverse reactions reported in patients treated with nerandomilast and more frequently than the placebo group were as follows for nerandomilast 18 mg, 9 mg and placebo, respectively: diarrhea (42%, 31%, 17%), COVID-19 (13%, 16%, 12%), upper respiratory tract infection (13%, 11%, 10%), depression (12%, 11%, 10%), weight decreased (11%, 10%, 8%), decreased appetite (9%, 9%, 5%), nausea (8%, 9%, 7%), fatigue (7%, 8%, 6%), headache (7%, 6%, 5%), vomiting (6%, 5%, 5%), back pain (6%, 5%, 4%) and dizziness (5%, 6%, 5%).2 Discontinuation due to adverse reactions occurred more frequently in patients treated with nerandomilast (with or without background antifibrotic treatment) 18 mg (15%) and 9 mg (12%) compared to placebo (11%).2 The most frequent adverse reaction leading to discontinuation of nerandomilast 18 mg and 9 mg was diarrhea (6% and 2%, respectively).2 There is no ‘Warnings and Precautions’ section in the FDA approved product label.2 “The FDA approval of nerandomilast is exciting news for people living with idiopathic pulmonary fibrosis and their caregivers,” said Scott Staszak, President and CEO of the Pulmonary Fibrosis Foundation. “There has been a long-standing need for new treatment options for IPF within our community and nerandomilast provides an important addition to the care landscape.” IPF is one of the more common progressive fibrosing interstitial lung diseases.1 It is deadlier than many forms of cancer, with a lower five-year survival rate compared to prostate cancer, female breast cancer and colon cancer.5,6 IPF substantially impacts quality of life and half of patients succumb to the disease within five years of diagnosis.7,8 In IPF, the root cause of pulmonary fibrosis is not known.1 Symptoms and signs of IPF include a dry and persistent cough, shortness of breath, fatigue and finger clubbing (widening and rounding of the topics of the fingers).9 IPF may affect up to 3.6 million people worldwide, and an estimated 200,000 people in the U.S.10-13 The disease primarily affects people over the age of 50 and affects more men than women.14 Nerandomilast is an oral, preferential inhibitor of PDE4B approved in the U.S. for the treatment of IPF in adult patients.2 Nerandomilast was approved by the FDA after securing Priority Review and Breakthrough Therapy Designation. Regulatory submissions for nerandomilast in IPF are also under review in China, Japan, and the EU, with filings in other geographies to follow. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. References Sauleda J, Núñez B, Sala E, Soriano JB. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med Sci (Basel). 2018;6(4):110. doi:10.3390/medsci6040110. JASCAYD (nerandomilast) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2025. Richeldi, Luca, Azuma, Arata, Cottin, Vincent, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. NEJM. 2025; 392:2193-2202. doi: 10.1056/NEJMoa2414108. Twisk JWR et al. (1998). Tracking of lung function parameters and the longitudinal relationship with lifestyle. European Respiratory Journal. 12(3):627–634. Zheng Q, Cox IA, Campbell JA, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 2022 Mar 14;8(1):00591-2021. doi: 10.1183/23120541.00591-2021. PMID: 35295232; PMCID: PMC8918939. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. PMID: 38230766. Swigris JJ, Brown KK, Abdulqawi R, et al. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 21;27(150):180075. doi: 10.1183/16000617.0075-2018. PMID: 30578334; PMCID: PMC9489034. Tsubouchi K, Hamada N, Tokunaga S, et al. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry. BMJ Open Respiratory Research. 2023;10:e001864. https://doi.org/10.1136/bmjresp-2023-001864. Alsomali H, Palmer E, Aujayeb A, Funston W. Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review. Pulm Ther. 2023 Jun;9(2):177-193. doi: 10.1007/s41030-023-00216-0. Epub 2023 Feb 11. Erratum in: Pulm Ther. 2023 Sep;9(3):459. doi: 10.1007/s41030-023-00235-x. PMID: 36773130; PMCID: PMC10203082. Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197. doi:10.1186/s12931-021-01791-z. Esposito DB, Lanes S, Donneyong M, et al. Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1200-7. doi: 10.1164/rccm.201504-0818OC. PMID: 26241562. Monthly Population Estimates for the United States: April 1, 2020 to December 1, 2022 (NA-EST2021-POP). US Census Bureau, Population Division; 2021. Accessed October 1, 2025. https://www2.census.gov/programs-surveys/popest/tables/2020-2021/national/totals/NA-EST2021-POP.xlsx Monthly Population Estimates for the United States: April 1, 2010 to December 1, 2013. US Census Bureau, Population Division; 2012. Accessed October 1, 2025. https://www2.census.gov/programs-surveys/popest/tables/2010-2012/national/totals/PEPMONTHN.pdf John, J., Clark, A.R., Kumar, H. et al. Pulmonary vessel volume in idiopathic pulmonary fibrosis compared with healthy controls aged > 50 years. Sci Rep 13, 4422 (2023). https://doi.org/10.1038/s41598-023-31470-6. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical ResultBreakthrough Therapy

10 Oct 2025

·www.fiercepharma.com

How Boehringer Ingelheim is buttressing its US business

None With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market.In this week’s episode of “The Top Line,” we dive into Boehringer Ingelheim’s latest regulatory successes, two crucial launches, and the German company’s expanding commercialization push in the U.S.Fierce Pharma’s Fraiser Kansteiner sits down with Brian Hilberdink—who joined Boehringer as president of U.S. human pharma in February—to discuss his game plan to further unlock the American market and capitalize on key BI green lights in idiopathic pulmonary fibrosis and lung cancer.To learn more about the topics in this episode: Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med HernexeosBoehringer Ingelheim breathes new life into lung fibrosis field with FDA approval for Jascayd'Crossing fingers': Boehringer awaits key FDA decisions to spearhead 'maturing' pipelineChutes & Ladders—Boehringer snatches up LEO exec for US pharma team

Drug ApprovalExecutive Change

100 Deals associated with Nerandomilast

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Norway KS	07 Oct 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Progressive pulmonary fibrosis	NDA/BLA	China	Boehringer Ingelheim Pharma GmbH & Co., KG	15 May 2025
Progressive pulmonary fibrosis	NDA/BLA	China	Boehringer Ingelheim International GmbH	15 May 2025
Idiopathic Interstitial Pneumonias	Phase 3	United States	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Japan	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Argentina	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Belgium	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	France	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Germany	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Italy	Boehringer Ingelheim GmbH	23 Jan 2026
Idiopathic Interstitial Pneumonias	Phase 3	Netherlands	Boehringer Ingelheim GmbH	23 Jan 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05321082 \| NCT05321069 (FIBRONEER-ILD, Company_Website) Manual	Phase 3	Idiopathic Pulmonary Fibrosis \| Progressive pulmonary fibrosis	2,353	Placebo	ctqvhuaclr(khqzjbfebt) = Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity). jdzrinepbv (wkxtlmlwqj ) Met View more	Positive	29 Sep 2025
				Nerandomilast 9 mg
NCT05321069 (FIBRONEER-IPF, CTgov)	Phase 3	Idiopathic Pulmonary Fibrosis	1,177	Placebo (Placebo)	qnmyhgyeyg(zhlexmguxc) = zkbihnkwxh tfzwwoosal (oavnxepynh, wuteubpgov - wfwtjsokru) View more	-	12 Sep 2025
				BI 1015550 (Nerandomilast 9 mg BID)	qnmyhgyeyg(zhlexmguxc) = kpcrbloext tfzwwoosal (oavnxepynh, ctadnefvbn - guqweykect) View more
NCT05321082 (FIBRONEER-ILD, Pubmed \| N Engl J Med)	Phase 3	Progressive pulmonary fibrosis	1,176	Nerandomilast 18 mg	zithppcbqv(rwicdmpamu) = eulmyuiaoi tiafmknfpg (ewjpfxpnsu, -123.7 to -73.4)	Positive	12 Jun 2025
				Nerandomilast 9 mg	zithppcbqv(rwicdmpamu) = qsuiraiwpj tiafmknfpg (ewjpfxpnsu, -109.6 to -59.7)
NCT05321082 (FIBRONEER-ILD, Literature \| NEWS) Manual	Phase 3	Progressive pulmonary fibrosis	1,176	Nerandomilast 18 mg twice daily	dcdcrcsylw(bkjthnmsyk) = hdsyrjocly evemcbvmls (vzbtknnlfo, -123.7 to -73.4) Met View more	Positive	19 May 2025
				Nerandomilast 9 mg twice daily	dcdcrcsylw(bkjthnmsyk) = welvdprqjn evemcbvmls (vzbtknnlfo, -109.6 to -59.7) Met View more
NCT05321069 (FIBRONEER-IPF, Pubmed \| NEWS) Manual	Phase 3	Idiopathic Pulmonary Fibrosis	1,177	Nerandomilast 18 mg	nbsqbegorl(lshyuxcxon) = klsrgsarho clauydoeox (gpsqqrwcfz, -141.8 to -87.5) Met View more	Positive	18 May 2025
				Nerandomilast 9 mg	nbsqbegorl(lshyuxcxon) = xmaihwqisy clauydoeox (gpsqqrwcfz, -165.6 to -111.6) Met View more
ATS2025	Phase 3	Pulmonary Atelectasis	-	Nerandomilast	fmgotlcugs(lphdcmgcez) = The signals derived from nerandomilast were strongly localized in the bronchial epithelium, whereas nintedanib was evenly detected throughout the lung tissue rrngotvedc (cwmwvwppkw ) View more	-	16 May 2025
				Nintedanib
NCT05321082 (FIBRONEER-ILD, NEWS) Manual	Phase 3	Fibrosis	1,178	nerandomilast 9 mg or 18 mg dose	bxxxhmcril(kwytrzgjfx) = The study hit its primary endpoint. nbcdcnpkbb (uzsfhowkwj ) Met View more	Positive	10 Feb 2025
				placebo
NCT05321069 (FIBRONEER-IPF, Biospace) Manual	Phase 3	Idiopathic Pulmonary Fibrosis	1,177	nerandomilast	wkorplhxjo(dgdqfkysrb) = Phase III trial in a decade to meet its primary endpoint. xwzprwhtji (ddgasnyzgv ) Met	Positive	24 Sep 2024
				Placebo
NCT04419506 (Phase 2 \| 1305-0013, CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	147	Placebo (Placebo - Antifibrotics at Baseline)	motermhrdv(vffpgmkckg) = vhaxmcypcf hfmrnaltjw (nzyixjlshl, gabxmysksr - dhcbibymhu) View more	-	01 Nov 2022
				prifenidone+pirfenidone+BI 1015550+nintedanib (BI 1015550 - Antifibrotics at Baseline)	motermhrdv(vffpgmkckg) = xpvzkhkved hfmrnaltjw (nzyixjlshl, qmfvhmfqal - mowcfoicbe) View more
NCT04419506 (1305-0013, Pubmed \| N Engl J Med)	Phase 2	Idiopathic Pulmonary Fibrosis	147	JASCAYD 18 mgJASCAYD 18 mg	ffvktoeumt(qhzqolkimz) = bwrjvbhyep wwvlfenlja (ajspefrrkb, -39.1 to 50.5) View more	Positive	09 Jun 2022
				Placebo	ffvktoeumt(qhzqolkimz) = qozrynqhyp wwvlfenlja (ajspefrrkb, -133.5 to -44.8) View more